Corporate GovernanceApr 30, 2026, 06:23 AM
LTRN Amends 10-K to Add Governance, Compensation Details
AI Summary
Lantern Pharma Inc. filed an Amendment No. 1 to its Annual Report on Form 10-K for the year ended December 31, 2025, to include previously omitted information for Part III, Items 10 through 14. This amendment provides detailed disclosures on directors, executive officers, corporate governance, executive compensation, and security ownership. Key updates include a stock option repricing approved in September 2025 and a summary of executive and non-executive director compensation for 2025.
Key Highlights
- Amendment to Original Form 10-K to include Part III information (Items 10-14).
- Stock option repricing approved Sept 19, 2025, for options with exercise prices between $10.21-$15.21 to $5.04.
- CEO Panna Sharma's 2025 total compensation: $763,750 (vs $1,090,634 in 2024).
- CFO David R. Margrave's 2025 total compensation: $585,580 (vs $752,886 in 2024).
- CSO Kishor G. Bhatia's 2025 total compensation: $244,424 (vs $539,120 in 2024).
- Total shares outstanding as of April 17, 2026: 11,304,697.
- All Officers and Directors as a group beneficially own 9.21% of common stock.
- Biological Mimetics, Inc. beneficially owns 7.47% of common stock.
Price Impact
More from LTRN